Legislative History
| House Bill/Resolution NO. House Bill No. 3302, 12th Congress of the Republic | |
| FULL TITLE : AN ACT ENHANCING THE COMPETITIVENESS AND ESTABLISHING THE SELF-RELIANCE OF THE NATIONAL PHARMACEUTICAL INDUSTRY, APPROPRIATING FUNDS THEREFOR, AND FOR OTHER PURPOSES | |
| ABSTRACT : "National Pharmaceutical Industries Omnibus Act of 1999". Rationale: A profile of the Philippine pharmaceutical industry reveals that it is oligopolistic in structure, dominated by foreign corporation or multinational companies (MNC's) cornering almost ninety percent (90%) of the total market for pharmaceuticals , mostly composed of branded leading products. Distribution channels for drugs and medicines are likewise composed of foreign multinational firms distributing the products of the manufacturers. Filipino-owned and -controlled companies manufacturing and distributing generic drugs and medicines comprise only 12% to 15% of the total market. This bill, therefore, seeks to address those concerns: >1. Establishment of an effective drugg regulatory system; 2. Provision of safe, affordable and accessible drugs and medicines; and 3. Initiation of ways and means to increase the global competitiveness and self-reliance of the local pharmaceutical industry. | |
| PRINCIPAL AUTHOR/S : TAGANAS LAYUS, CELIA | |
| DATE FILED : 2001-09-28 | |
| SIGNIFICANCE: NATIONAL | |
| CO-AUTHORS (Journal Entries) : | |
| 1. Lozada (035 ) | 2. Syjuco (067 ) |
| ADMINISTRATION BILL? No | |
| URGENT BILL? No | |
| ACTIONS TAKEN BY THE COMMITTEE ON RULES | |
| REFERRAL TO THE COMMITTEE ON TRADE AND INDUSTRY ON 2001-10-08 | |
| SECONDARILY REFERRED TO THE COMMITTEE(S) ON WAYS AND MEANS, APPROPRIATIONS |
Abstract
"National Pharmaceutical Industries Omnibus Act of 1999". Rationale: A profile of the Philippine pharmaceutical industry reveals that it is oligopolistic in structure, dominated by foreign corporation or multinational companies (MNC's) cornering almost ninety percent (90%) of the total market for pharmaceuticals , mostly composed of branded leading products. Distribution channels for drugs and medicines are likewise composed of foreign multinational firms distributing the products of the manufacturers. Filipino-owned and -controlled companies manufacturing and distributing generic drugs and medicines comprise only 12% to 15% of the total market. This bill, therefore, seeks to address those concerns: >1. Establishment of an effective drugg regulatory system; 2. Provision of safe, affordable and accessible drugs and medicines; and 3. Initiation of ways and means to increase the global competitiveness and self-reliance of the local pharmaceutical industry.
Disclaimer
Note: Legislative history and other information accessed from Congress Legis. Information as of April 20, 2022.